<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03960411</url>
  </required_header>
  <id_info>
    <org_study_id>01</org_study_id>
    <nct_id>NCT03960411</nct_id>
  </id_info>
  <brief_title>Effect of Doxycycline on Cardiac Remodelling in STEMI Patients</brief_title>
  <official_title>Effect of Doxycycline on Cardiac Remodelling in Patients With ST-Elevation Myocardial Infarction (STEMI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Felix Chikita Fredy, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cardiovascular Center Harapan Kita Hospital Indonesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subsequent to the loss of myocardium post-myocardial infarction (MI), the affected ventricle
      undergoes some dynamic structural and functional changes known as remodeling. Cardiac
      remodeling progresses into heart failure (HF). In this revolutionized percutaneous coronary
      intervention (PCI) era, the incidence of post-MI HF due to cardiac remodeling remains high.
      Current standard therapeutic interventions, for HF, aimed solely at correcting a low cardiac
      output do not necessarily impede HF progression. Recently, doxycycline was found to have an
      additional biological effect aside from their antimicrobial actions. From several
      experimental studies and clinical trials, doxycycline showed MMP inhibition activities that
      can prevent ventricular remodeling. This study aims to evaluate the role of doxycycline in
      cardiac remodeling prevention post-MI. Our hypothesis is that a better heart function will be
      observed in STEMI patients who receive a short period of doxycycline administration post-PCI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2019</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>One arm receives standard care after primary PCI, the other receives doxycycline b.i.d for 7 days as an adjunct to standard care</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The only party who is not masked is the pharmacist</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>high sensitivity-Troponin T</measure>
    <time_frame>12 hours</time_frame>
    <description>hs-Troponin T in ng/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>high sensitivity-CRP</measure>
    <time_frame>24 hours</time_frame>
    <description>hs-CRP in mg/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NT-pro BNP</measure>
    <time_frame>5 days</time_frame>
    <description>NT-pro BNP in pg/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>netrophils</measure>
    <time_frame>24 hours</time_frame>
    <description>absolute amount per micro liters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ST2</measure>
    <time_frame>24 hours</time_frame>
    <description>ST2 in ng/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>4 months</time_frame>
    <description>The number of deceased participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure incidence</measure>
    <time_frame>4 months</time_frame>
    <description>Evaluating the occurrence of heart failure signs and/or symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalization rate</measure>
    <time_frame>4 months</time_frame>
    <description>The number of patients re-admitted due to heart failure signs and/or symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricle function and dimension</measure>
    <time_frame>4 months</time_frame>
    <description>Assessed through echocardiography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <condition>Anterior Wall Myocardial Infarction</condition>
  <condition>Heart Failure</condition>
  <condition>Remodeling, Ventricular</condition>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxycycline 100 mg capsule by mouth every 12 hours for 7 days, administered early after primary PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule by mouth every 12 hours for 7 days, administered early after primary PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 100Mg Capsule</intervention_name>
    <description>Doxycycline capsule</description>
    <arm_group_label>Doxycycline</arm_group_label>
    <other_name>Doryx</other_name>
    <other_name>Doxyhexal</other_name>
    <other_name>Doxylin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Capsule manufactured to mimic doxycycline 100 mg capsule</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo (for Doxycycline)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Onset of STEMI &lt;12 hours

          -  Anterior wall STEMI or Killip grade II-III or LVEF &lt;50%

          -  Undergoing primary PCI

        Exclusion Criteria:

          -  Signs of infection (clinical judgement plus leukocyte count &gt;15,000)

          -  STEMI mechanical complication

          -  Moderate-severe valvular disease

          -  Allergic to doxycycline

          -  Refuse to join the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bambang Widyantoro, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indonesia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bambang Widyantoro, PhD</last_name>
    <phone>+62 812 8164299</phone>
    <email>bambang_ui@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Felix C Fredy, MD</last_name>
    <phone>+62 821 12099811</phone>
    <email>felixchikita@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cardiovascular Center Harapan Kita Hospital</name>
      <address>
        <city>Jakarta</city>
        <zip>11420</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bambang Widyantoro, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Bambang Widyantoro, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felix C Fredy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arief A Subakti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anindita Suputri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <link>
    <url>http://academic.oup.com/eurheartj/article/35/3/184/492844</url>
    <description>TIPTOP Trial</description>
  </link>
  <reference>
    <citation>Cerisano G, Buonamici P, Valenti R, Sciagr√† R, Raspanti S, Santini A, Carrabba N, Dovellini EV, Romito R, Pupi A, Colonna P, Antoniucci D. Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial. Eur Heart J. 2014 Jan;35(3):184-91. doi: 10.1093/eurheartj/eht420. Epub 2013 Oct 8.</citation>
    <PMID>24104875</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Felix Chikita Fredy, MD</investigator_full_name>
    <investigator_title>cardiology resident</investigator_title>
  </responsible_party>
  <keyword>Doxycycline</keyword>
  <keyword>Cardiac Remodelling</keyword>
  <keyword>STEMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Anterior Wall Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

